Fukui T, Sasaki J, Igawa S, Kada A, et al. Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040). BMC Cancer 2022;22:1314.
PMID: 36522630